HaemaLogiX’s CAR-Ts to feature at 4th National Myeloma Workshop
11 October 2022
HaemaLogiX is pleased to announce that both its CAR-T technology and its therapeutic targets will be showcased at Myeloma Australia’s 4th National Myeloma Workshop in Victoria on October 2022.
Dr Mary Sartor (Westmead Institute for Medical Research) will speak on the relevance of HaemaLogiX’s targets, Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen, (LMA) for multiple myeloma patients who have relapsed and/or become refractory to existing treatments.
Associate Professor Jane Oliaro (Peter MacCallum Cancer Centre) will talk on the development of our lead therapy, the monoclonal antibody KappaMab, into CAR-T cells, which is a form of immunotherapy of which two products were recently approved by the FDA.
Myeloma Australia’s 4th National Myeloma Workshop, “Pathways to a Cure", runs 21 – 23 October 2022.